​​Educational background

• Medical physics residency, BC Cancer, Canada (2021-23)
• PhD, Physics (Medical Physics Stream), University of British Columbia, BC, Canada (2020)
  
• BSc, Physics, University of Victoria, BC, Canada (2013)
  

Publications

• Robertson, A.K.H., McNeily, B.L., Fu, W., Yang, H., Hoehr, C., Ramogida, C.F. & Schaer, P. (2021). Production, purification, and radiolabeling of the 212Pb/203Pb theranostic pair, EJNMMI Radiopharmacy and Chemistry 6.
  
• Robertson, A.K.H., Kunz, P., Hoehr, C. & Schaer, P. (2020). Nuclide production cross sections from irradiation of thorium by 438 MeV protons and a comparison to FLUKA and GEANT4 simulations, Physical Review C 102.
• Robertson, A.K.H., McNeil, B.L., Yang, H., Gendron, D., Perron, R., Radchenko, V., Zeisler, S., Causey, P. & Schaer, P. (2020). 232Th-spallation-produced 225Ac with reduced 227Ac content, Inorganic Chemistry 59.
• Li, L., Rousseau, J., Jaraquemada-Pelaez, M.G., Wang, X., Robertson, A., Radchenko, V., Schaer, P., Lin, K., Benard, F. & Orvig, C. (2020). 225Ac-H4py4pa for targeted alpha therapy, Bioconjugate Chemistry 31.
  
• Ramogida, C.F., Robertson, A.K.H., Jermilova, U., Zhang, C., Yang, H., Kunz, P., Lassen, J., Bratanovic, I., Brown, V., Southcott, L., Rodriguez-Rodriguez, C., Radchenko, V., Benard, F., Orvig, C. & Schaer, P. (2019). Evaluation of polydentate picolinic acid chelating ligands and a melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac, EJNMMI Radiopharmacy and Chemistry 4.
• Robertson, A.K.H., Lobbezoo, A., Moskven, L., Schaer, P. & Hoehr, C. (2019). Design of a thorium metal target for 225Ac production at TRIUMF, Instruments 3.
• Robertson, A.K.H., Ramogida, C.F., Schaer, P. & Radchenko, V. (2018). Development of 225Ac-radiopharmaceuticals: TRIUMF perspectives and experiences, Current Radiopharmaceuticals 11.
• Robertson, A.K.H., Crawford, J.R., Yang, H., Rodriguez-Rodriguez, C., Esquinas, P.L., Kunz, P., Blinder, S., Sossi, V., Schaer, P. & Ruth, T.J. (2018). Evaluation of 209At as a theranostic isotope for 211At-radiopharmaceutical development using high-energy SPECT, Physics in Medicine and Biology 63.
• Thiele, N., Brown, V., Kelly, J.M., Amor-Coarasa, A., Jermilova, U., MacMillan, S.N., Nikolopoulou, A., Ponnala, S., Ramogida, C.F., Robertson, A.K.H., Rodriguez-Rodriguez, C., Schaer, P., Williams, C., Babich, J.W., Radchenko, V. & Wilson, J.J. (2017). An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy, Angewandte Chemie 56.
• Robertson, A.K.H., Ramogida, C.F., Rodriguez-Rodriguez, C., Blinder, S., Kunz, P., Sossi, V. & Schaer, P. (2016). Multi-isotope SPECT imaging of the 225Ac decay chain: Feasibility studies. Physics in Medicine and Biology 62.